

UNITED STATES
PATENT AND
TRADEMARK OFFICECommissioner for Patents
Washington, DC 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/928,267	08/10/2001	Fodor	33

CONFIRMATION NO. 6575

Mark Farber
c/o Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410

FORMALITIES LETTER



OC000000008849463

12/17/2002 NPRASASO 00000019 010483 09928267
01 FC:1051 130.00 CH

Date Mailed: 09/25/2002

NOTICE TO FILE MISSING PARTS OF NONPROVISIONAL APPLICATION

FILED UNDER 37 CFR 1.53(b)

Adjustment date: 12/17/2002 NPRASASO
12/01/2002 SLUANG1 00000004 010483 09928267
01 FC:2051 65.00 CR

Filing Date Granted

Items Required To Avoid Abandonment:

An application number and filing date have been accorded to this application. The item(s) indicated below, however, are missing. Applicant is given **TWO MONTHS** from the date of this Notice within which to file all required items and pay any fees required below to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

- The oath or declaration is missing.
A properly signed oath or declaration in compliance with 37 CFR 1.63, identifying the application by the above Application Number and Filing Date, is required.
- Late filing fee or oath or declaration surcharge as set forth in 37 CFR 1.16(e) of \$130 was not received.

The application is informal since it does not comply with the regulations for the reason(s) indicated below.

The required item(s) identified below must be timely submitted to avoid abandonment:

- A substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125, is required. The specification, claims, or abstract page(s) submitted is not acceptable and cannot be scanned or properly stored because:
 - The line spacing on the specification, claims, or abstract is not 1-1/2 or double spaced (see 37 CFR 1.52(b)).
- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable

12/02/2002 SLUANG1 00000004 010483 09928267

\$5.00 CH

form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

SUMMARY OF FEES DUE:

Total additional fee(s) required for this application is **\$130** for a Large Entity

- **\$130** Late oath or declaration Surcharge.

*A copy of this notice **MUST** be returned with the reply.*



Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE



Docket No.: 33US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fodor et al.

Serial No.: 09/928,267

Examiner: Unassigned

Filed: August 10, 2001

Group: Unassigned

For: ENGINEERED RECOMBINANT MOLECULE THAT REGULATES HUMORAL
AND CELLULAR EFFECTOR FUNCTIONS OF THE IMMUNE SYSTEM

RESPONSE TO NOTICE TO FILE MISSING PARTS

Asst. Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to File Missing Parts of Application mailed September 25, 2002, Applicant encloses herewith a properly executed Combined Declaration and Power of Attorney executed by the inventor as well as a substitute specification in compliance with 37 CFR 1.52, 1.121(b)(3), and 1.125, along with a copy of the Notice to File Missing Parts of Application.

A Notification of Change in Large Entity Status Under 37 CFR 1.28(b) as well as an executed Assignment are also enclosed.

The Commissioner is hereby authorized to charge the \$65.00 surcharge for filing the Declaration, to Deposit Account No. 01-0483. Kindly charge any additional fees associated with this petition or credit any overpayment to Deposit Account No. 01-0483. **TWO DUPLICATE COPIES OF THIS SHEET ARE ENCLOSED.**

Date: 11/22/02

Mark Farber
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410

Respectfully Submitted,

Mark Farber
Reg. No. 34,159
Attorney for Applicants



Docket No.33 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Fodor et al.
Serial No.: 09/928,267
Filed: August 10, 2001
For: ENGINEERED RECOMBINANT MOLECULE THAT
REGULATES HUMORAL AND CELLULAR EFFECTOR
FUNCTIONS OF THE IMMUNE SYSTEM

CERTIFICATE OF MAILING

Date of Deposit: 11/22/02

I hereby certify that the following:

- ☒ This Certificate of Mailing
- ☒ Response to Notice to File Missing Parts
- ☒ Copy of Notice to File Missing Parts
- ☒ Declaration and Power of Attorney
- ☒ 37 Pages of Substitute Specification
- ☒ Notification of Change in Large Entity Status
- ☒ Assignment
- ☒ Assignment Recordal Sheet

are being deposited with the United States Postal Service first-class mail on the Date of Deposit indicated above in an envelope addressed to the ATTN: Assistant Commissioner of Patents, Washington, D.C. 20231.


Lori Rooney

Mark Farber
C/O
Alexion Pharmaceuticals, Inc.
352 Knotter Drive
Cheshire, CT 06410